Status:
COMPLETED
Simvastatin Reduces Circulating Osteoprotegerin Levels in Patients With Type 2 Diabetes
Lead Sponsor:
University of Aarhus
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
Diabetes is associated with dyslipidaemia leading to generalized atherosclerosis, cardiovascular disease (CVD) and nephropathy. Osteoprotegerin (OPG), a glycoprotein involved in bone homeostasis, has ...
Detailed Description
Type 2 diabetes is associated with an increased risk of macro- and microvascular complications, resulting from a generalized injury to the vascular endothelium. The pathophysiological mechanisms leadi...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Persistent microalbuminuria
- Fasting plasma cholesterol \> 5.5 mmol/liter
- Fasting plasma triglycerides \< 4.5 mmol/liter
- Fasting HbA1c \< 10 %
- Fasting serum C-peptide \> 0.49 nmol/liter
- Blood pressure \< 155/95
Exclusion
- Signs of primary kidney disease
- Signs of primary hepatic disease
- Signs of insufficiently treated cardiac disease
Key Trial Info
Start Date :
June 1 1991
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 1993
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00471549
Start Date
June 1 1991
End Date
December 1 1993
Last Update
May 10 2007
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.